ArticleGenes & diseases2024

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma.

Jing Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.